A Phase 1 interventional study of BMS-791325 and BMS-791325 in Hepatitis C Virus, sponsored by Bristol-Myers Squibb. Withdrawn at 1 site in United States. Open to participants aged 20 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-18.
Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics following single oral and multiple oral doses BMS-791325 in healthy Japanese subjects.
2,356 studies on the registry are indexed under Hepatitis C; 101 are open to participants now.
Browse Hepatitis C studies →Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 118 are open to participants now.
Of its 435 completed or terminated interventional studies of FDA-regulated products, 227 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: BMS-791325 · Drug: Placebo
Drug: BMS-791325 · Drug: Placebo
Drug: BMS-791325 · Drug: Placebo
Drug: BMS-791325 · Drug: Placebo
Drug: BMS-791325 · Drug: Placebo
Drug: BMS-791325 · Drug: Placebo
Capsules, Oral, 300 mg, Single Dose, One day
Capsules, Oral, 900 mg, Single Dose, One day
Capsules, Oral, ≤1200 mg, Single Dose, One day
Capsules, Oral, 300 mg, Every 12 hours, 14 days
Capsules, Oral, 900 mg, once daily 14 days
Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days
Capsules, Oral, Single Dose, One day
Capsules, Oral, Every 12 hours, 14 days
Capsules, Oral, Once Daily, 14 days
Capsules, Oral, Every 12 hours or once daily, 14 days
Safety (adverse events, physical examinations, clinical labs, ECGs, vital signs)
Time frame: From time of dose to up to 14 days after last dose
To measure concentration of study drug following single and multiple doses
Time frame: Within 48 or 72 hours postdose
This study is withdrawn, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Beclabuvir